212 related articles for article (PubMed ID: 22033576)
1. Heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) emerged before the clinical introduction of vancomycin in Japan: a retrospective study.
Yamakawa J; Aminaka M; Okuzumi K; Kobayashi H; Katayama Y; Kondo S; Nakamura A; Oguri T; Hori S; Cui L; Ito T; Jin J; Kurosawa H; Kaneko K; Hiramatsu K
J Infect Chemother; 2012 Jun; 18(3):406-9. PubMed ID: 22033576
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
[TBL] [Abstract][Full Text] [Related]
3. High prevalence of a globally disseminated hypervirulent clone, Staphylococcus aureus CC121, with reduced vancomycin susceptibility in community settings in China.
Shen P; Zhou K; Wang Y; Song J; Liu Y; Zhou Y; Xiao Y
J Antimicrob Chemother; 2019 Sep; 74(9):2537-2543. PubMed ID: 31203362
[TBL] [Abstract][Full Text] [Related]
4. Impact of vancomycin use trend change due to the availability of alternative antibiotics on the prevalence of Staphylococcus aureus with reduced vancomycin susceptibility: a 14-year retrospective study.
Kang YR; Kim SH; Chung DR; Ko JH; Huh K; Cho SY; Kang CI; Peck KR
Antimicrob Resist Infect Control; 2022 Aug; 11(1):101. PubMed ID: 35932086
[TBL] [Abstract][Full Text] [Related]
5. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA).
Howden BP
Intern Med J; 2005 Dec; 35 Suppl 2():S136-40. PubMed ID: 16271057
[TBL] [Abstract][Full Text] [Related]
6. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
Mirza HC; Sancak B; Gür D
Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.
Matsuo M; Cui L; Kim J; Hiramatsu K
Antimicrob Agents Chemother; 2013 Dec; 57(12):5843-53. PubMed ID: 24018261
[TBL] [Abstract][Full Text] [Related]
8. Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
Katayama Y; Murakami-Kuroda H; Cui L; Hiramatsu K
Antimicrob Agents Chemother; 2009 Aug; 53(8):3190-6. PubMed ID: 19451283
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin.
Srisrattakarn A; Chaiyapoke C; Booncharoen S; Wongthong S; Chanawong A; Tippayawat P; Tavichakorntrakool R; Lulitanond A
Turk J Med Sci; 2021 Aug; 51(4):2150-2158. PubMed ID: 33705643
[TBL] [Abstract][Full Text] [Related]
10. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
[TBL] [Abstract][Full Text] [Related]
11. Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011.
Hanaki H; Cui L; Ikeda-Dantsuji Y; Nakae T; Honda J; Yanagihara K; Takesue Y; Matsumoto T; Sunakawa K; Kaku M; Tomono K; Fukuchi K; Kusachi S; Mikamo H; Takata T; Otsuka Y; Nagura O; Fujitani S; Aoki Y; Yamaguchi Y; Tateda K; Kadota J; Kohno S; Niki Y
J Infect Chemother; 2014 Sep; 20(9):527-34. PubMed ID: 25066429
[TBL] [Abstract][Full Text] [Related]
12. Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates.
Zhang S; Sun X; Chang W; Dai Y; Ma X
PLoS One; 2015; 10(8):e0136082. PubMed ID: 26287490
[TBL] [Abstract][Full Text] [Related]
13. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.
Shariati A; Dadashi M; Moghadam MT; van Belkum A; Yaslianifard S; Darban-Sarokhalil D
Sci Rep; 2020 Jul; 10(1):12689. PubMed ID: 32728110
[TBL] [Abstract][Full Text] [Related]
14. Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study.
Martirosov DM; Bidell MR; Pai MP; Scheetz MH; Rosenkranz SL; Faragon C; Malik M; Mendes RE; Jones RN; McNutt LA; Lodise TP
BMC Infect Dis; 2017 Aug; 17(1):534. PubMed ID: 28764660
[TBL] [Abstract][Full Text] [Related]
15. Molecular characteristics and virulence factors in methicillin-susceptible, resistant, and heterogeneous vancomycin-intermediate Staphylococcus aureus from central-southern China.
Liu C; Chen ZJ; Sun Z; Feng X; Zou M; Cao W; Wang S; Zeng J; Wang Y; Sun M
J Microbiol Immunol Infect; 2015 Oct; 48(5):490-6. PubMed ID: 24767415
[TBL] [Abstract][Full Text] [Related]
16. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
Appelbaum PC
Int J Antimicrob Agents; 2007 Nov; 30(5):398-408. PubMed ID: 17888634
[TBL] [Abstract][Full Text] [Related]
17. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore.
Fong RK; Low J; Koh TH; Kurup A
Eur J Clin Microbiol Infect Dis; 2009 Aug; 28(8):983-7. PubMed ID: 19387707
[TBL] [Abstract][Full Text] [Related]
18. A mutation of RNA polymerase β' subunit (RpoC) converts heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) into "slow VISA".
Matsuo M; Hishinuma T; Katayama Y; Hiramatsu K
Antimicrob Agents Chemother; 2015 Jul; 59(7):4215-25. PubMed ID: 25941225
[TBL] [Abstract][Full Text] [Related]
19. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center.
Lin SY; Chen TC; Chen FJ; Chen YH; Lin YI; Siu LK; Lu PL
J Microbiol Immunol Infect; 2012 Dec; 45(6):435-41. PubMed ID: 22749725
[TBL] [Abstract][Full Text] [Related]
20. [The incidence and risk factors for heterogeneous vancomycin intermediate Staphylococcus aureus].
Feng NN; Wang Q; Song YL; He LX; Zhou CM; Xie HM; Li HY
Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):318-22. PubMed ID: 23925360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
